Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: A case report

Journal of Medical Case Reports

Volumn 3, Issue , 2009, Pages

  Patel, Supen R ^a  

^a Carolina Health Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PREDNISONE;

ACID FAST BACTERIUM; ADULT; ANEMIA; ARTICLE; BONE MARROW BIOPSY; BONE MARROW DISEASE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; HYPERTENSION; LABORATORY TEST; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SARCOIDOSIS; SPLENOMEGALY; SYSTEMIC DISEASE; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 72449207653     PISSN: 17521947     EISSN: 17521947     Source Type: Journal    
DOI: 10.4076/1752-1947-3-8573     Document Type: Article

References (20)

1. Sarcoidosis. LS Newman CS Rose LA Maier, N Engl J Med 1997 336 1224 1234 10.1056/NEJM199704243361706 9110911
2. Differential diagnoses of bone marrow granuloma. A Eid W Carion JS Nystrom, West J Med 1996 164 510 515 8764626
3. Clinical characteristics of patients in a case control study of sarcoidosis. RP Baughman AS Teirstein MA Judson MD Rossman H Yeager Jr EA Bresnitz L DePalo G Hunninghake MC Iannuzzi CJ Johns G McLennan DR Moller LS Newman DL Rabin C Rose B Rybicki SE Weinberger ML Terrin GL Knatterud R Cherniak Case Control Etiologic Study of Sarcoidosis (ACCESS) research group, Am J Respir Crit Care 2001 164 1885 1889 11734441
4. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. KU Ulbricht M Stoll J Bierwirth T Witte RE Schmidt, Arthritis Rheum 2003 48 3542 3543 10.1002/art.11357 14674007
5. Treatment of sarcoidosis with infliximab. JD Doty JE Mazur MA Judson, Chest 2005 127 1064 1071 10.1378/chest.127.3.1064 15764796
6. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. AM Yee MB Pochapin, Ann Intern Med 2001 135 27 31 11434729
7. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. L Mallbris A Ljungberg MA Hedblad P Larsson M Ståhle-Bäckdahl, J Am Acad Dermatol 2003 48 290 293 10.1067/mjd.2003.228 12582407
8. Refractory sarcoidosis responding to infliximab. SD Roberts DS Wilkes RA Burgett KS Knox, Chest 2003 124 2028 2031 10.1378/chest.124.5.2028 14605086
9. Tumor necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. C Pritchard K Nadarajah, Ann Rheum Dis 2004 63 318 320 10.1136/ard.2002.004226 14962969
10. Treatment of therapy-resistant sarcoidosis with adalimumab. JL Callejas-Rubio N Ortego-Centeno L Lopez-Perez MN Benticuaga, Clin Rheumatol 2005 25 596 597 10.1007/s10067-005-0037-9 16247590
11. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. RP Baughman M Drent M Kavuru MA Judson U Costabel R du Bois C Albera M Brutsche G Davis JF Donohue J Müller-Quernheim R Schlenker-Herceg S Flavin KH Lo B Oemar ES Barnathan Sarcoidosis Investigators, Am J Respir Crit Care Med 2006 174 795 802 10.1164/rccm.200603-402OC 16840744
12. Adalimumab for treatment of cutaneous sarcoidosis. MP Heffernan DI Smith, Arch Dermatol 2006 142 17 19 10.1001/archderm.142.1.17 16415380
13. What is the future of methotrexate in sarcoidosis. A study and review. VM Vucinic, Curr Opin Pulm Med 2002 8 470 476 10.1097/00063198-200209000-00022 12172455
14. Bedford Laboratories 2005
15. Sanofi-Aventis 2007
16. Roche Laboratories Inc 2008
17. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. GR Burmester PJ Mease BA Dijkmans K Gordon D Lovell R Panaccione J Perez AL Pangan, Ann Rheum Dis 2009 19147611
18. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. JP Utz AH Limper S Kalra U Specks JP Scott Z Vuk-Pavlovic DR Schroeder, Chest 2003 124 177 185 10.1378/chest.124.1.177 12853521
19. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. A Menter SK Tyring K Gordon AB Kimball CL Leonardi RG Langley BE Strober M Kaul Y Gu M Okun K Papp, J Am Acad Dermatol 2008 58 106 115 10.1016/j.jaad.2007.09.010 17936411
20. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. JF Colombel WJ Sandborn P Rutgeerts MA Kamm AP Yu EQ Wu PF Pollack KG Lomax J Chao PM Mulani, Am J Gastroenterol 2009 104 1170 1179 10.1038/ajg.2009.59 19352339